Prefilled, Disposable Insulin Pen With Half-Unit Dosing Now Available

By October 12, 2017

The Humalog Junior KwikPen is lighter and shorter than other half-unit insulin pens.

Better Risk Factor Modification Strategies Needed for Optimal Stroke Prevention

October 12, 2017

Increases in prevalence of hypertension, diabetes, dyslipidemia, smoking, and drug abuse in AIS

Co-Occurrence of Autoimmunities for Diabetes, Celiac Disease Examined

October 11, 2017

The researchers found that IAs alone, tTGAs alone, and both appeared in 367, 808, and 90 children, respectively, with co-occurrence significantly exceeding the expected rate.

Insulin Pump Therapy Linked to Better Outcomes in Young T1D Patients

October 11, 2017

Compared with injection therapy, pump therapy was correlated with lower rates of severe hypoglycemia (9.55 versus 13.97 per 100 patient-years) and diabetic ketoacidosis (3.64 versus 4.26 per 100 patient-years).

Can Frequent Mouthwash Use Up the Risk of Prediabetes/Diabetes?

By October 06, 2017

Study authors explained that using antibacterial mouthwash can eradicate oral microbes needed for nitric oxide formation and place the user at risk for metabolic disorders.

Do SGLT2 Inhibitors Increase Cancer Risk in T2D Patients?

October 06, 2017

Overall cancer risk not increased compared with placebo, other active glucose-lowering treatments

Dosing Information Updated for Rapid-Acting Inhaled Insulin Afrezza

By October 02, 2017

Specifically, the key highlights of the label update include new study data that describe the time-action profile by dosage strength of Afrezza as well as clarity on "starting" and "adjusting" mealtime dose.

New Glucose-Sensing Device Eliminates Need for Routine Finger Sticks

By September 29, 2017

A trial (Dunn T et al. 2017) of ≥50,000 diabetes patients, that lasted 18 months, found that FreeStyle Libre users checked their glucose on average 16 times a day.

FDA Approves Fiasp for Patients with Type 1, Type 2 Diabetes

By September 29, 2017

Fiasp is formulated with niacinamide which helps increase the speed of the initial insulin absorption.

Impact of Liraglutide vs. Lifestyle Changes in Prediabetic, T2D Patients

September 26, 2017

Significant improvement in IGF-II serum levels were found with liraglutide for obese with prediabetes, early T2DM

Many First Line Diabetes Treatment Failures Down to Nonadherence

September 25, 2017

An additional second-line antihyperglycemic medication or insulin was more likely in patients given their initial second-line medication without evidence of recommended use of metformin (P<0.001).

Increased Med Use Over Time Seen in Older Patients of All BMI Classes

By September 22, 2017

Researchers aimed to determine whether the rise in prescription drug use over time varied by age and obesity status.

Long-Term Outcomes of Roux-en-Y Gastric Bypass

September 21, 2017

The researchers found that the adjusted mean changes from baseline in body weight in the surgery group were −45.0, −36.3, and −35.0 kg at 2, 6, and 12 years, respectively.

Humalog Junior KwikPen Soon to Be Available

By September 19, 2017

Humalog Junior KwikPen U-100 will be available as 5-count cartons. The BD pen needles are recommended for use with Humalog Junior KwiKPen.

Effects of Anagliptin vs. Alogliptin on Lipid Profile of T2D Patients

September 19, 2017

The researchers found that there was no significant difference in percent change in LDL-C level between the 2 groups at 24 weeks.

Outcomes Examined for Continuous Glucose Monitoring During Pregnancy

September 18, 2017

Compared with controls, pregnant women with CGM spent more time in target and less time hyperglycemic.

Death Risk Up in T2D Patients Following Severe Hypoglycemia Episode

By September 18, 2017

Patients with type 2 diabetes who experience severe hypoglycemia may be at an increased risk of death following the episode.

Investigational Skin Patch Delivers Fat-Burning Drug to Targeted Areas

By September 15, 2017

The patches mechanism of action turns white adipose tissue into brown adipose tissue, white tissue is known to store fat while brown tissue is known to burn fat to produce heat.

Do SGLT2 Inhibitors Raise the Risk of Lower Extremity Amputation?

By September 15, 2017

Study authors analyzed the occurrence of amputation in patients with type 2 diabetes mellitus treated with SGLT2 inhibitors vs. non-SGLT2 inhibitors, and specifically, canagliflozin.

Evolocumab Safe, Effective in Patients with Diabetes

By September 15, 2017

Compared to placebo, Repatha was not associated with an increased risk of developing new-onset diabetes or worsening glycemia over a median follow-up period of 2.2 years in patients without diabetes at baseline.

Cardiovascular Effects of Exenatide Tx Examined in T2D

September 14, 2017

The researchers found that 11.4% of patients in the exenatide group and 12.2% in the placebo group had a primary composite event (hazard ratio, 0.91; 95% confidence interval, 0.83 to 1.00); in the intention-to-treat analysis.

Coffee Consumption and Mortality in Diabetes: What's the Link?

September 14, 2017

Compared with women who did not consume caffeine, women who consumed caffeine had an adjusted hazard ratio for death of 0.49 for <100 mg caffeine/day, 0.43 for 100 to <200mg/day, and 0.34 for ≥200 mg caffeine/day (P=0.007).

Novel Adjunct Therapy Improves Glycemic Control in T1D

September 14, 2017

The researchers found that the proportion of patients achieving the primary end point (glycated hemoglobin level <7.0% at week 24, with no episodes of severe hypoglycemia or diabetic ketoacidosis) was significantly larger in the sotagliflozin versus the placebo group.

Anti-Incretin Effect Demonstrated with Intestinal Glucose Stimulation

September 13, 2017

The difference was greater in obese subjects, and declined to normal following BPD. No evidence was found for glucose malabsorption.

Cardiovascular Benefits Seen with Xultophy in T2D Patients

By September 13, 2017

The data came from a post-hoc analysis of two randomized-controlled trials that compared Xultophy to insulin degludec (DUAL II) and to insulin glargine U100 (DUAL V).

Additional Data from EMPA-REG OUTCOME Announced

By September 12, 2017

During the study period (4.6 years) 12.1% of placebo group participants primary endpoint compared to 10.4% (Empagliflozin 10mg) and 10.5% (Empagliflozin 25mg) (P<0.0001).

Biomarkers ID'd That May Enhance Prediction of Renal Function Decline

September 11, 2017

The researchers found in an eGFR trajectory analysis that 10.1% of participants were rapid decliners, with a mean decrease of 2.9 mL/min/1.73 m²/year.

Admelog Tentatively Approved for Diabetes Mellitus

By September 05, 2017

Pending any patent issues that have yet to be resolved by the Company, the FDA has concluded that the product has met all necessary regulatory requirements for approval.

Test Predicts Elderly Patients' Ability to Learn Insulin Self-Injection Technique

September 05, 2017

Number of animal names recalled in one minute was the most useful indicator

Long-Term Effects of Liraglutide on Renal Outcomes Examined in T2DM

September 01, 2017

Prespecified secondary analysis shows benefit for liraglutide when added to usual care in T2DM